Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

Efficacy and Safety of Home-based Structured Physical Exercise in Patients With Acute Ischemic Stroke

NCT07271082 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2025-12-18
Last updated
2026-09-21

Condition(s) studied

Acute Ischemic Stroke

Investigational drug(s) / intervention(s)

Exercise intervention

Exercise intervention: Subjects will undergo 90 days of home-based structured physical exercise guidance.

Study summary

This study is a randomized controlled, open-label, blinded endpoint trial. The investigators aim to assess the efficacy and safety of home-based structured physical exercise in participants with acute ischemic stroke.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age 18 years or greater, male or female; 2. Acute ischemic stroke onset within 14 days; 3. modified Rankin scale (mRS) score ≤ 3; 4. Signed informed consent from the patients or the legally authorized representatives. Exclusion Criteria: 1. Stroke progression within the past 3 days (defined as an increase in NIHSS score of ≥4 points or an increase in any single item of ≥2 points); 2. Concurrent osteoarthritis, fractures, deep vein thrombosis, unstable angina, severe heart diseases, respiratory diseases, or amputation that may theoretically make it difficult for participants to complete the physical exercise or ambulation; 3. Concurrent movement disorders such as Parkinson's disease or Parkinsonism; 4. Patients who have engaged in regular aerobic physical activity within the past 6 months, defined as more than 150 minutes of moderate-intensity aerobic physical activity; or more than 75 minutes of vigorous-intensity aerobic physical activity; or an equivalent combination of moderate- and vigorous-intensity activity throughout the week; 5. Unable to comply with the study procedures or follow-up due to psychiatric, cognitive, or emotional disorders; 6. Known pregnancy or lactation, or a positive pregnancy test; 7. Currently participating in another drug or device study; 8. Life expectancy less than 1 year; 9. Unable to communicate using a smartphone; 10. Other conditions considered by investigators to be unsuitable for inclusion.

Primary outcome measure(s)

  • Change in 6-Minute Walk Test Distance — Between baseline and 90 days

Trial sites (6)

FacilityCityRegionStatus
Taihe Hospital of Traditional Chinese Medicine Fuyang Anhui
Suzhou Municipal Hospital Suzhou Anhui
Beijing Pinggu District Hospital Beijing Beijing Municipality
Xihua County People's Hospital Zhoukou Henan
Shihezi People's Hospital Shihezi Xinjiang
Xuanwu Hospital, Capital Medical University, 100053 Beijing China
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07271082 on ClinicalTrials.gov ↗ ← All trials in China